| Literature DB >> 28239299 |
Norlaily Mohd Ali1, Swee Keong Yeap2, Nadiah Abu3, Kian Lam Lim1, Huynh Ky4, Ahmad Zaim Mat Pauzi5, Wan Yong Ho6, Sheau Wei Tan7, Han Kiat Alan-Ong1, Seema Zareen8, Noorjahan Banu Alitheen5, M Nadeem Akhtar8.
Abstract
AIMS: Curcumin is a lead compound of the rhizomes of Curcuma longa and possess a broad range of pharmacological activities. Chemically, curcumin is 1,3-dicarbonyl class of compound, which exhibits keto-enol tautomerism. Despite of its strong biological properties, curcumin has yet been recommended as a therapeutic agent because of its poor bioavailability. MAINEntities:
Keywords: Apoptosis; CDC2 phosphorylation; Cell cycle arrest; DK1; ROS
Year: 2017 PMID: 28239299 PMCID: PMC5320730 DOI: 10.1186/s12935-017-0400-3
Source DB: PubMed Journal: Cancer Cell Int ISSN: 1475-2867 Impact factor: 5.722
Fig. 1Synthesis of (Z)-3-hydroxy-1-(2-hydroxyphenyl)-3-phenylprop-2-en-1-one (DK1)
The accession number and sequence of the primers used in the quantitative real-time PCR assay
| Accession number | Gene | Sequence |
|---|---|---|
| NM_001101.3 | ACTB | F: 5′-AGAGCTACGAGCTGCCTGAC-3′ |
| NM_002046.4 | GAPDH | F: 5-GGATTTGGTCGTATTGGGC-3 |
| HQ387008.1 | 18S rRNA | F: 5-GTAACCCGTTGAACCCCATT-3 |
| NM_005030.3 | PLK1 | F: 5-CCTGCACCGAAACCGAGTTAT-3 |
| NM_001143976.1 | WEE-1 | F: 5-GGGAATTTGATGTGCGACAG-3 |
| NM_001220778.1 | p21 | F: 5-TGTCCGTCAGAACCCATGC-3 |
The values of IC50 of DK1 in MCF-7, MDA-MB231 and MCF-10A
| Cell lines | 24 h | 48 h | 72 h | |||
|---|---|---|---|---|---|---|
| DK1 (µM) | Curcumin (µM) | DK1 (µM) | Curcumin (µM) | DK1 (µM) | Curcumin (µM) | |
| HL-60 | 137.61 ± 2.16 | 57.01 ± 3.75 | 123.85 ± 3.27 | 29.86 ± 3.11 | 73.39 ± 2.65 | 21.72 ± 1.76 |
| HepG2 | >150 ± 5.85 | 67.86 ± 2.88 | 137.61 ± 4.13 | 40.72 ± 2.76 | 64.22 ± 3.12 | 24.43 ± 2.25 |
| MCF-7 | 96.83 ± 4.87 | 40.72 ± 3.24 | 33.33 ± 3.50 | 36.58 ± 2.31 | 25.00 ± 3.71 | 30.15 ± 2.36 |
| MDA-MB-231 | 104.17 ± 5.23 | 35.29 ± 4.16 | 45.83 ± 4.66 | 21.72 ± 1.87 | 37.50 ± 4.82 | 21.72 ± 3.18 |
| MCF-10A | >208 | 190.02 ± 3.67 | 125.83 ± 3.67 | 114.01 ± 3.57 | 104.17 ± 5.21 | 100.44 ± 3.17 |
| Selective index of MCF-10A/MCF-7 | >2.17 | 4.67 | 3.75 | 3.50 | 4.17 | 3.33 |
| Selective index of MCF-10A/MDA | >2.00 | 5.38 | 2.72 | 5.25 | 2.77 | 4.63 |
Fig. 2a, b Light and c, d fluorescent microscopic analysis of control and DK1 treated MCF-7 cell after 72 h of incubation. Cells in c, d were stained with acridine orange and propidium iodide. e Bar chart analysis of the percentage of viable, apoptotic and late apoptotic/necrotic of control and DK1 treated MCF-7 cells via fluorescent microscopic count of 200 cells. The experiment was done in triplicate and the data are expressed as mean ± SE with (*p < 0.05)
Fig. 3Flow cytometry Annexin V apoptosis of control and DK1 (25 µM) treated MCF-7. The experiment was done in triplicate and the data are expressed as mean ± SE with (*p < 0.05)
Fig. 4Detection of the activation of caspase 9, cytochrome c, GSH and ROS levels in the control and DK1 (25 μM) treated MCF-7 cells. The experiment was done in triplicate and the data are expressed as mean ± SE with (*p < 0.05)
Fig. 5Differential protein expression of. a Western blot analysis of CDC2, p-CDC2 and p53 in MCF-7 treated with DK1 (25 μM) for 24, 48 and 72 h. b Differential protein level of control and DK1 (25 μM) treated MCF-7 cells normalised to β-actin. The experiment was done in triplicate and the data are expressed as mean ± SE with *p < 0.05
Fig. 6Flow cytometry cycle progression analyses of control and DK1 (25 µM) treated MCF-7. The experiment was done in triplicate and the data are expressed as mean ± SE with (*p < 0.05)
Fig. 7qPCR analysis of cell cycle related genes; PLK1, p21 and WEE-1 in MCF-7 treated with DK1 (25 μM) for 24, 48, and 72 h. The experiment was done in triplicate and the data are expressed as mean ± SE with (*p < 0.05)